Hemocompatibility in hemodialysis and erythropoietin therapy
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu klinické zkoušky, časopisecké články, práce podpořená grantem
- MeSH
- akrylové pryskyřice metabolismus MeSH
- beta-thromboglobulin metabolismus MeSH
- celulosa analogy a deriváty metabolismus MeSH
- dialýza ledvin * MeSH
- dospělí MeSH
- ELISA MeSH
- erythropoetin aplikace a dávkování terapeutické užití MeSH
- histokompatibilita MeSH
- komplement C5a metabolismus MeSH
- krevní proteiny metabolismus MeSH
- lidé středního věku MeSH
- lidé MeSH
- membrány umělé MeSH
- rekombinantní proteiny aplikace a dávkování terapeutické užití MeSH
- trombocyty cytologie účinky léků MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- práce podpořená grantem MeSH
- Názvy látek
- akrylové pryskyřice MeSH
- beta-thromboglobulin MeSH
- celulosa MeSH
- cuprammonium cellulose MeSH Prohlížeč
- erythropoetin MeSH
- komplement C5a MeSH
- krevní proteiny MeSH
- membrány umělé MeSH
- polyacrylonitrile MeSH Prohlížeč
- rekombinantní proteiny MeSH
Two studies designed to investigate the effect of recombinant human erythropoietin (rHuEPO) treatment of anemia in chronic dialysis patients on hemocompatibility were conducted. Study 1, whose main aim was to establish whether treatment with rHuEPO enhances coagulation activation during dialysis, included 15 patients before rHuEPO therapy at a mean hematocrit (HCT) of 22.3% and then during therapy at a HCT of 29.3%. The plasma concentrations of the thrombin-antithrombin III complex were not higher during rHuEPO therapy than before it when performing hemodialysis with a Cuprophan membrane. No significant difference was demonstrated either in the values of activated clotting times (Hemochron), thrombocyte or white blood cell counts (Coulter S+II), or in plasma C5a concentrations (ELISA) established during dialysis sessions before and during rHuEPO therapy. In Study 2, which focused primarily on the question of whether or not rHuEPO therapy increases thrombocyte activation during hemodialysis, 8 patients on chronic dialysis were examined both before therapy at a mean HCT value of 22.1% and during rHuEPO therapy at a HCT of 31.5%, invariably during dialysis with either a Cuprophan or polyacrylonitrile (AN69HF) membrane. The plasma concentrations of beta-thromboglobulin (ELISA) did not differ between the examinations made during rHuEPO and before rHuEPO therapy; however, statistically significant differences were found between dialysis sessions involving Cuprophan and AN69HF membranes. No significant difference between examination before and during rHuEPO was demonstrated in activated clotting time nor thrombocyte and white blood cell counts in this study either. The authors conclude that rHuEPO therapy does not enhance coagulation activation during hemodialysis, does not have an effect on thrombocyte activation, and does not influence complement activation and changes in white blood cell counts.
Citace poskytuje Crossref.org